Switzerland· 57872001
Vectibix 100 mg/5 ml, Konzentrat zur Herstellung einer Infusionslösung
A panitumumab product containing panitumumabum, registered in Switzerland by Amgen Switzerland AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Panitumumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FE02 (panitumumab), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 8 of them publish a price we can compare per daily dose
Panitumumab · ATC L01FE02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- panitumumabum
- Manufacturer
- Amgen Switzerland AG
- Country
- Switzerland (CH)
- ATC code
- L01FE02
- ATC class
- Panitumumab
- Defined daily dose
- 30 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680578720017Durchstf 5 mlCHF 426.9
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
27 interactions on record for panitumumab.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Panitumumab · interactions on record
27 records
- 14 severe
- 13 moderate
Most severe, free to view
- AmiodaroneC01BD01severe
- DofetilideC01BD04severe
- DronedaroneC01BD07severe
- IrinotecanL01CE02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Panitumumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainVECTIBIX 20 mg/ml CONCENTRADO PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- United StatesVectibixAmgen, Inc
- BelgiumVectibix 20 mg/mlAmgen Europe
- United KingdomVectibix 100mg/5ml concentrate for solution for infusion vialsAmgen Ltd
- FinlandVectibixAmgen Europe B.V.
- CanadaVECTIBIXAMGEN CANADA INC
- Japanパニツムマブ(遺伝子組換え)武田薬品工業
- CzechiaVECTIBIXAmgen Europe B.V., Breda
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Vectibix
- Norway · Vectibix
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/02942966-169e-4328-bd2d-8442553144b6 GET /v1/drugs/02942966-169e-4328-bd2d-8442553144b6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "panitumumabum 100 mg",
"valid_from": "2010-05-01",
"limitations": "[{\"description\":\"Nur nach vorgängiger Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes:<br>\\nZur Behandlung von Patienten mit metastasierendem kolorektalem Karzinom mit RAS-Wildtyp<br>\\n-\\tIn der First-Line-Therapie in Kombination mit FOLFOX oder FOLFIRI. <br>\\n-\\tIn der Second-Line-Therapie in Kombination mit einer Irinotecan-haltigen Chemotherapie. <br>\\n-\\tAls Monotherapie, wenn Therapien mit Fluoropyrimidin-, Oxaliplatin- und Irinotecan-haltigen Chemotherapien versagt haben oder nicht durchführbar waren.<br>\\nIm Falle einer Progression ist die Vectibix-Behandlung abzubrechen.\\n\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2019-12-01\"}]",
"galenic_form": "Inf Konz 100 mg/5ml",
"therapeutic_area": null,
"sl_inclusion_date": "2010-05-01",
"self_retention_pct": 10
}See everything about panitumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.